Piramal Pharma Ltd vs Walpar Nutritions Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Piramal Pharma Ltd is ₹ 161.9 as of 30 Apr 15:30 . The P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 yearsThe P/E Ratio of Walpar Nutritions Ltd changed from 32.1 on March 2022 to 17.1 on March 2025 . This represents a CAGR of -14.57% over 4 years The Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 yearsThe Market Cap of Walpar Nutritions Ltd changed from ₹ 12.26 crore on March 2022 to ₹ 39.72 crore on March 2025 . This represents a CAGR of 34.16% over 4 years The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The revenue of Walpar Nutritions Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The ebitda of Walpar Nutritions Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The net profit of Walpar Nutritions Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 yearsThe Dividend Payout of Walpar Nutritions Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

About Walpar Nutritions Ltd

Walpar Nutritions Limited was originally formed and registered as a Partnership Firm in the name and style of 'M/s Walpar Healthcare', pursuant to a Deed of Partnership dated November 16, 2009.
Subsequently, the Constitution of Partnership Firm were changed on March 9, 2015, August 15, 2017 and June 12, 2020 by admission and retirement of Partners. 'M/s.
Walpar Healthcare' was thereafter converted from a erstwhile Partnership Firm to a Public Limited Company as 'Walpar Nutritions Limited' and received a Certificate of Incorporation dated December 4, 2020 from the Central Registration Center, Ministry of Corporate Affairs.
The Company is primarily engaged in manufacturing, marketing and trading of Pharmaceuticals, Nutraceutical, Herbal and Ayurvedic commodities online and offline. The Company made a public issue of 12,00,000 Equity Shares of having Face Value of Rs.

FAQs for the comparison of Piramal Pharma Ltd and Walpar Nutritions Ltd

Which company has a larger market capitalization, Piramal Pharma Ltd or Walpar Nutritions Ltd?

Market cap of Piramal Pharma Ltd is 21,520 Cr while Market cap of Walpar Nutritions Ltd is 34 Cr

What are the key factors driving the stock performance of Piramal Pharma Ltd and Walpar Nutritions Ltd?

The stock performance of Piramal Pharma Ltd and Walpar Nutritions Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Piramal Pharma Ltd and Walpar Nutritions Ltd?

As of May 3, 2026, the Piramal Pharma Ltd stock price is INR ₹161.9. On the other hand, Walpar Nutritions Ltd stock price is INR ₹37.0.

How do dividend payouts of Piramal Pharma Ltd and Walpar Nutritions Ltd compare?

To compare the dividend payouts of Piramal Pharma Ltd and Walpar Nutritions Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.